Implementation Facilitation Pilot for Alcohol Use Disorder (AUD) in Alcohol-associated Liver Disease (ALD)
Yale University · with National Institute on Alcohol Abuse and Alcoholism (NIAAA) · NCT07525258
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18+ · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 30
- US sites recruiting
- 1
- Study start
- April 5, 2026
- Record last updated
- May 7, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The goal of this project is to improve provision of integrated medications for alcohol use disorder (MAUD) with brief counseling for patients with alcohol use disorder (AUD) and alcohol-associated liver disease (ALD) in hepatology clinics. There are many benefits of AUD treatment among patients with AUD and ALD such as reduction in liver-related complications and hepatology clinicians providing this care in an integrated fashion can improve access and uptake.
Being studied: Implementation Intervention
Conditions: Alcohol Use Disorder; Alcohol-associated Liver Disease
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Must provide care for patients with liver disease at a hepatology clinical location within the Yale School of Medicine and YNHH medical system.
Exclusion Criteria
- Providers who do not treat patients with chronic liver disease and alcohol-associated liver disease.
Recruiting US locations
Yale School of Medicine/Yale-New Haven Health
New Haven, CT 06520
Study contacts (from the official record)
- Lamia Haque, MD MPH · (203) 777-0304 · lamia.haque@yale.edu
Similar studies in Connecticut
All healthy volunteers studies in Connecticut →- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Study to Learn How Different Amounts of the Study Medicine Called PF-08103402 Are Tolerated and Act in the Body in Healthy Adults or Adults With Mild To-moderate Asthma
Pfizer
- Location
- New Haven, CT
- Eligibility basics
- Ages 18–65
- RecruitingHealthy volunteersEarly Phase 1Overnight stay mentioned
Investigating the Mu:Kappa Opioid Receptor Imbalance in Alcohol Use Disorder
Yale University
- Location
- New Haven, CT
- Eligibility basics
- Ages 21–70
- RecruitingHealthy volunteersPhase 1
MK-0947 PN-002: An Open-label Study to Evaluate Brain α-synuclein Deposition Using Positron Emission Tomography (PET) and [¹⁸F]MK-0947 in Participants With Parkinson's Disease (PD)
XingImaging, LLC
- Location
- New Haven, CT
- Eligibility basics
- Ages 40–80
- RecruitingHealthy volunteersEarly Phase 1
A Study of the Pharmacokinetics, Biodistribution and Dosimetry of Granzyme-B Targeted [Cu-64]-Labeled PET Radiotracers in Adult Healthy Volunteers
Ratio Therapeutics, Inc.
- Location
- New Haven, CT
- Eligibility basics
- Ages 18–60